A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis

Mol Genet Metab. 2007 Nov;92(3):274-7. doi: 10.1016/j.ymgme.2007.07.004. Epub 2007 Aug 14.

Abstract

We report a recessive mutation in the tyrosine hydroxylase gene (TH) promoter (c.1-71C>T), present at homozygosity in a patient with dopa-responsive encephalopathy. The change lies in a cAMP response element (CRE) and alters a binding site for the CREM transcription factor. Previous studies support that the CRE in the TH gene is essential for its transcription, suggesting that mutations within this consensus motif may cause an impairment of catecholamine biosynthesis and lead to a pathogenic phenotype.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Damage, Chronic / drug therapy*
  • Child
  • Child, Preschool
  • Cyclic AMP / pharmacology
  • Dihydroxyphenylalanine / therapeutic use*
  • Dopamine Agents / therapeutic use*
  • Female
  • Gene Expression Regulation, Enzymologic*
  • Homozygote
  • Humans
  • Point Mutation / genetics*
  • Promoter Regions, Genetic / genetics*
  • Response Elements / genetics*
  • Transcription, Genetic
  • Tyrosine 3-Monooxygenase / genetics*

Substances

  • Dopamine Agents
  • Dihydroxyphenylalanine
  • Cyclic AMP
  • Tyrosine 3-Monooxygenase